Cycloferon solution for intravenous and intramuscular administration of ampoules 2 ml 5 pcs
Condition: New product
976 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Meglumine acridone acetate
Release form
Solution
Composition
Active ingredient: Meglumine acridone acetate (Meglumine acridonatetate) Active ingredient concentration (mg): 125
Pharmacological effect
Immunomodulator Meglumin acridone acetate is a low molecular weight inducer of interferon, which determines a wide range of its biological activity (antiviral, immunomodulatory, anti-inflammatory). Interferonogenic activity of the drug when administered orally is maintained for 3 days. The main cells producing interferon after administration of the drug are macrophages, T-and B-lymphocytes. The drug induces high titers of interferon in organs and tissues containing lymphoid elements (spleen, liver, lungs), activates bone marrow stem cells, stimulating the formation of granulocytes. Cycloferon activates T-lymphocytes and natural killer cells, normalizes the balance between T-helper and T-suppressor subpopulations. Enhances the activity of α-interferon. It has a direct antiviral effect, inhibiting the reproduction of the virus in the early stages (1-5 days) of the infectious process, reducing the infectivity of viral offspring, leading to the formation of defective viral particles. Increases nonspecific resistance of the organism against viral and bacterial infections. Cycloferon is effective against tick-borne encephalitis viruses, influenza, hepatitis, herpes, cytomegalovirus, human immunodeficiency virus, papilloma virus and other viruses. In acute viral hepatitis, Cycloferon prevents the transition of diseases to the chronic form. At the stage of primary manifestations of HIV infection helps stabilize immunity indicators. The high efficacy of the drug in the complex therapy of acute and chronic bacterial infections (neuroinfection, chlamydia, bronchitis, pneumonia, postoperative complications, urogenital infections, peptic ulcer) as a component of immunotherapy. Meglumine acridone acetate shows high efficacy in rheumatic and systemic connective tissue diseases, suppressing autoimmune reactions and exerting anti-inflammatory and analgesic effects.
Pharmacokinetics
Tablets After taking the drug inside the maximum allowable dose of Cmax in the blood plasma is reached after 2-3 hours, the concentration gradually decreases by 8 hours, after 24 hours the active substance is detected in trace amounts. T1 / 2 is 4-5 hours. When using Cycloferon in recommended doses, there are no conditions for its cumulation in the body. Solution for injection When administered in the maximum permissible dose, Cmax in the blood plasma is reached in 1-2 hours. After 24 hours, the active substance is detected in trace amounts. It penetrates through BBB. T1 / 2 is ie 4-5 hours. With prolonged use of cumulation in the body is not observed.
Indications
In adults, in complex therapy: HIV infections (stages 2A - 2B), neuroinfections: serous meningitis and encephalitis, tick-borne borelliosis (Lyme disease), viral hepatitis A, B, C, D, herpes and cytomegalovirus infection, secondary immunodeficiencies associated with acute and chronic bacterial and fungal infections; chlamydial infections; rheumatic and systemic diseases of the connective tissue (rheumatoid arthritis, systemic lupus erythematosus); degenerative-dystrophic diseases of the joints: deforming osteoarthrosis, etc. in complex therapy: viral hepatitis A, B, C, D; herpes infection, HIV - infection (step 2A-2B)
Contraindications
Pregnancy, lactation, hypersensitivity to the components of the drug, decompensated liver cirrhosis, children under 4 years of age.
Precautionary measures
In diseases of the thyroid gland, cycloferon should be administered under the supervision of an endocrinologist.
Use during pregnancy and lactation
The drug is contraindicated for use during pregnancy and lactation (breastfeeding).
Dosage and administration
1. In adults: CYCLOFERON is administered intramuscularly or intravenously once a day according to the basic scheme: every other day. The duration of treatment depends on the disease.1.1 For herpes and cytomegalovirus infection according to the basic scheme 10 injections of 0.25 g. The total dose of 2.5 g. The treatment is most effective at the beginning of the exacerbation of the disease. 1.2 In neuroinfections, the drug is administered according to the basic scheme. The course of treatment is 12 injections of 0.25-0.5 g in combination with etiotropic therapy. A cumulative dose of 3-6 g. Repeated courses as needed.1.3 In case of chlamydial infection, it is administered according to the basic scheme. The course of treatment 10 injections of 0.25 g.The total dose of 2.5 g. Repeated treatment in 10-14 days. It is advisable to combine CYCLOPHERON with antibiotics.1.4 For acute viral hepatitis A, B, C, D and mixed forms, the drug is injected according to the basic scheme of 10 injections of 0.5 g. The total dose of 5.0 g. 14 days. In chronic viral hepatitis B, C, D and mixed forms, the drug is administered according to the basic scheme of 10 injections of 0.5 g, followed by the maintenance scheme 3 times a week for three months as part of complex therapy. Recommended in combination with interferons and chemotherapy. Repetition of the course in 10–14 days.1.5 In case of HIV infection (2A-2B) according to the basic scheme of 10 injections of 0.5 g and then in the supporting scheme once every three days for 2.5 months. Repetition of the course in 10 days.1.6. In immunodeficient states, the course of treatment is 10 intramuscular injections according to the basic regimen in a single dose of 0.25 g. The total dose is 2.5 g. A repeated course is carried out in 6 - 12 months.1.7. 4 courses of 5 injections on the basic scheme of 0.25 g with an interval of 10-14 days. Repeated course on the recommendation of a doctor. 1.8 In degenerative-dystrophic diseases of the joints, 2 courses of 5 injections of 0.25 g each with a break of 10-14 days according to the basic scheme. Repeated course as recommended by a doctor In children: In pediatric practice, CYCLOFERON is used intramuscularly or intravenously once a day according to the basic scheme: every other day. The daily therapeutic dose is 6–10 mg / kg body weight.2.1 For acute viral hepatitis A, B, C, D, and mixed forms, the drug is administered according to the basic scheme of 15 injections. In case of a protracted course of infection, the course is repeated in 10-14 days.2.2. In chronic viral hepatitis B, C, D, the drug is administered according to the basic scheme of 10 injections and then under the supporting scheme three times a week for three months as part of complex therapy. It is recommended in combination with interferons and chemotherapy.2.3. For HIV infection (stages 2A-2B), a course of 10 injections according to the basic scheme and then under the supporting scheme once every three days for three months. A repeated course in 10 days. 2..4 With a herpes infection, a course of 10 injections according to the basic scheme. While maintaining the replicative activity of the virus, the course of treatment is continued in a maintenance regimen with the introduction every three days for four weeks.
Side effects
Allergic reactions.
Overdose
To date, no cases of overdose have been reported.
Interaction with other drugs
Cycloferon is compatible with all drugs used in the treatment of these diseases (including interferons and chemotherapeutic drugs). Cycloferon enhances the effect of interferons and nucleoside analogues. When combined, Cycloferon reduces the side effects of chemotherapy and interferon therapy.
special instructions
In the treatment of influenza and acute respiratory viral infections, in addition to cycloferon therapy, symptomatic therapy should be performed. Influence on the ability to drive vehicles and control mechanisms Cycloferon does not affect the ability to drive vehicles.